Bioventus Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing reports annual results; the provided text does not give clear standalone fourth-quarter financial results. Bioventus is a global medical-device company with U.S. and International reporting segments and three product groups: Pain Treatments, Surgical Solutions and Restorative Therapies. The U.S. generated 88% of 2023 net sales.
Key financial results
Amounts in millions of U.S. dollars, except per-share data and margins.
| Metric | 2023 | 2022 |
|---|---|---|
| Net sales | $512.3 | $512.1 |
| Gross profit / margin | $328.2 / 64.1% | $331.1 / 64.6% |
| Operating loss | $(81.7) | $(167.2) |
| Continuing-operations net loss | $(121.2) | $(144.7) |
| Consolidated net loss, including discontinued operations | $(195.6) | $(213.4) |
| Adjusted EBITDA (non-GAAP) | $88.9 | $68.6 |
| Class A diluted loss per share | $(2.49) | $(2.59) |
| Cash from continuing operating activities | $17.5 | $(11.4) |
- Revenue was essentially flat year over year. U.S. sales declined 1.2% to $449.9 million; International sales rose 9.9% to $62.5 million.
- By product group, U.S. Pain Treatments grew 1.6%, U.S. Surgical Solutions grew 7.0%, and U.S. Restorative Therapies declined 12.9%, mainly reflecting the Wound Business divestiture. International Surgical Solutions increased 29.9%.
- SG&A fell 8.5% to $303.9 million, and R&D fell 43.6% to $13.4 million. Operating results included a $78.6 million non-cash impairment of Wound Business intangible assets and a $3.6 million loss on disposals. The 2022 comparison included a $124.7 million goodwill impairment in continuing operations.
- Cash, cash equivalents and restricted cash were $37.0 million at year-end, versus $30.2 million in 2022. Continuing-operations investing cash flow was $27.3 million, including $34.7 million in Wound Business sale proceeds; continuing-operations financing cash flow was $(26.7) million.
- At December 31, 2023, current assets were $268.0 million and current liabilities were $175.5 million. Debt carrying value was $394.8 million: $382.4 million of term loans and $15.0 million drawn on the revolver, less unamortized costs and discount. The term loan and revolver carried rates of 9.89% and 9.88%, respectively. Cash less debt carrying value was approximately $357.9 million.
Material changes, outlook and risks
- Management attributed higher Adjusted EBITDA primarily to cost savings, lower bad debt and lower administrative and travel costs. Restructuring initiatives were expected to deliver annualized savings of $9–10 million. Adjusted EBITDA is a company-defined non-GAAP measure and excludes significant items.
- Bioventus sold specified Wound Business assets in May 2023 for $34.7 million at closing, $5.0 million deferred and up to $45.0 million in earn-outs tied to 2024–2026 sales thresholds. It used $30.0 million of proceeds to repay debt.
- In February 2023, the company transferred its CartiHeal interest to a trustee after it could not secure financing for the acquisition payment obligations. The transaction generated a $60.6 million disposal loss; total discontinued-operations loss was $74.4 million in 2023. CartiHeal reported no sales in 2022 or 2023.
- Debt covenants were amended in January 2024, after year-end, to provide additional flexibility. The company reported compliance with the covenants in effect at December 31, 2023, but future compliance depends on operating performance. The amended agreement includes a $10 million minimum monthly liquidity requirement during the specified period and leverage and interest-coverage tests. Management said it expected to meet obligations for the next 12 months, while warning that projections may prove inaccurate and further covenant changes or financing may be needed.
- Major risks include substantial debt and high interest expense; dependence on HA products, which represented 43% of 2023 revenue; payer reimbursement and rebate uncertainty; reliance on a limited number of suppliers; regulatory and product-approval risks; and possible disruption to Israeli manufacturing. Securities class-action Exchange Act claims remain in discovery, and two derivative cases are pending or subject to consolidation/stay discussions. The company says losses are not probable or reasonably estimable.
- Management reported that previously identified material weaknesses—including controls over rebates accruals and the control environment—were remediated by December 31, 2023. The filing also describes prior immaterial financial-statement errors and an $8.4 million rebate-related revenue adjustment in 2022. The auditor did not attest to internal-control effectiveness because of the company’s emerging-growth-company exemption.
- No specific financial guidance is provided in the supplied filing text. The stated strategy emphasizes HA market share, surgical product growth, R&D and selective international expansion. Robert Claypoole became CEO in January 2024.
Investor verification priorities
- Review the full debt amendment, covenant headroom, actual revolver availability and near-term debt-service requirements; the filing gives $15.0 million drawn and separately describes facility capacity and availability.
- Assess cash generation and whether cost savings can offset interest expense, reimbursement pressure and any working-capital needs.
- Verify the timing and likelihood of the Wound Business deferred consideration and earn-outs, and the effect of the divestiture on comparable segment sales.
- Track HA rebate accruals, reimbursement changes and concentration in HA products and key suppliers.
- Monitor securities litigation, regulatory developments affecting Exogen and HA products, and operational exposure from Israel and single-source suppliers.